REFERENCES
- Sweetman CS. Martindale: The Complete Drug Reference, 34th ed. London: Pharmaceutical Press, 2005; p. 41.
- Maurice DM. Kinetics of topically applied drugs. In: Ophthalmic Drug Delivery, Biopharmaceutical, Technological, and Clinical Aspects, Vol. II. Fidia Research Series. Padova, Italy: Liviana Press, 1987; pp. 19–26.
- Hecht G. Ophthalmic preparations. In: Gennaro AF (Ed.). Remington: The Science and Practice of Pharmacy, Vol. II. Easton, PA: Mack Publishing, 1995; p. 1563.
- Dey S, Patel J, Anand BS, et al. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest Ophthalmol Vis Sci. 2003;44:2909–2918.
- Karla PK, Pal D, Quinn T, et al. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int J Pharm. 2007;336:12–21.
- Duvvuri S, Majumdar S, Mitra AK. Role of metabolism in ocular drug delivery. Curr Drug Metab. 2004;5:507–515.
- Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136–1163.
- Zhang T, Xiang CD, Gale D, et al. Drug transporter and CYP P450 mRNA expression in human ocular barriers: Implications for ocular drug disposition. Drug Metab Dispos. 2008;36:1300–1307.
- Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacol Rev. 2006;58:140–161.
- Vega E, Gamisans F, García ML, et al. PLGA nanospheres for the ocular delivery of flurbiprofen sodium: Drug release and interactions. J Pharm Sci. 2008;97:5306–5317.
- Pignatello R, Bucolo C, Spedalieri G, et al. Flurbiprofen sodium-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247–3255.
- Vega E, Egea MA, Valls O, et al. Flurbiprofen sodium loaded biodegradable nanoparticles for ophthalmic administration. J Pharm Sci. 2006;95:2393–2405.
- Masuda K, Ikari T, Matsuyama T, Terashima A, Takao G, inventors: Kakenyaku Kako Co. Ltd., Japan, assignee. Antiinflammatory ophthalmic solution and process for preparing the same. US patent 4 474 811. October 2, 1984.
- Gurtler F, Gunny R. Patent literature review of ophthalmic inserts. Drug Del Ind Pharm. 1995;21:1–18.
- Chien YW. Ocular drug delivery and delivery systems. In: Novel Drug Delivery Systems. New York: Marcel Dekker Inc., 1996; pp. 269–301.
- Chiou GCY, Watanabe K. Drug delivery to the eye. Pharm Ther. 1982;17:269–278.
- Khar RK, Vyas SP. Targeted and Controlled Drug Delivery Novel Carrier Systems, 1st ed. New Delhi:CBS Publishers and Distributors, 2002; p. 384.
- Saettone MF, Salminen L. Ocular inserts for topical delivery. Adv Drug Del Rev. 1995;16:95–106.
- Castelli F, Messina C, Sarpietro MG, et al. Flurbiprofen sodium release from Eudragit RS and RL aqueous nanosuspensions: A kinetic study by DSC and dialysis experiments. AAPS PharmSciTech. 2006;3:1–8.
- Graber, H. Rational antibiotic therapy: New drugs, changing concepts. The Eastern Pharmacist. 1991;7:25–30.
- Dhanaraju MD, Sivakumar VR, Subhashree R, et al. Bioadhesive ocusert matrix for ophthalmic administration of ciprofloxacin hydrochloride. Indian Drugs. 2002;39:222–224.
- Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substance applied topically to the skin and mucous membrane. J Pharmacol Exp Ther. 1944;82:377–390.
- Dandagi PM, Manvi FV, Patil MB, et al. Development and evaluation of ocular films of cromolyn sodium. Indian J Pharm Sci. 2004;66:309–312.